APC & VLE Therapeutics, the Irish Multinational group, announce €100M expansion and 300 new jobs to establish ‘The Medicine Accelerator Campus’ in Cherrywood, Dublin

  • The Medicine Accelerator transforms how medicines are researched, digitised and manufactured


  • The business is currently working on 35+ medicines that transform patient treatment in areas such as oncology, respiratory disease, Alzheimer’s, HIV and more, at HQ in Dublin


  • Enterprise Ireland supports expansion and welcomes creation of high value pharma R&D, Digital & Manufacturing jobs and the strengthening of Ireland’s position in the global value chain of medicine development

The Medicine Accelerator, the Irish Multinational group responsible for breakthrough pharma process research and development (APC) and Manufacture (VLE), today announce a groundbreaking expansion that involves the creation of 300 new R&D jobs and a €100M capital expansion to form a globally unique Medicine Accelerator Campus in Cherrywood Dublin.

The 130,000 sq ft campus, the largest R&D site in the biopharma sector in Ireland and the expanded home for APC & VLE, will integrate the latest developments in scientific research, AI, neural networks and scientifically led manufacturing activities. This value chain is transforming medicine development and the time to patient for new and advanced therapeutics.

Partnering with eight of the top 10 pharmaceutical companies globally and a wide range of biotechs, APC & VLE works across a wide range of therapeutic areas. The business is currently working on 35+ medicines that transform patient treatment in areas such as oncology, respiratory disease, Alzheimer’s, HIV and more, at its HQ in Dublin.

Serving as a global research epicentre The Medicine Accelerator Campus represents one of the most disruptive businesses in pharmaceutical development, digitalization and manufacturing. At its core, this disruption will be facilitated by three interwoven strategic elements:

  1. Best-in-class Science: Advancing the boundaries of pharmaceutical process research and development through a world class team of scientific experts.
  2. First-in-class Digital: Accelerating medicine development and manufacturing outcomes through the application of our state-of-the-art digital technologies and Artificial Intelligence.
  3. Science-First Manufacturing: Driving manufacturing outcomes through industry-first scientific and digitalisation breakthroughs.

The group, which is fully Irish owned, is already the largest employer of R&D scientists, within the pharmaceutical sector, nationally. This addition of 300 new roles will bring the combined team to over 600 scientists, digital experts, and manufacturing professionals bringing The Medicine Accelerator team to a global stage.

This significant growth underscores the organisations dedication to fostering talent, and creating a powerhouse team to drive advancements in research, digital capabilities and manufacturing. The organisation has also developed iAchieve, a cutting-edge digitalisation platform that meticulously digitizes every facet of a medicine’s development and manufacturing journey. This digital transformation is a step change in medicine R&D and presents huge opportunity for medicine acceleration through AI and other advanced digital applications.

Mark Barrett, CEO and Co-Founder of APC & VLE Therapeutics, says the expansion solidifies APC & VLE’s commitment to advancing innovation in the global pharmaceutical industry.

“Reimagining how medicines are developed and accelerated to patients is our motivation, our purpose. Today’s announcement of an additional 300 new jobs, along with a €100 million capital plan to create a new 130,000 ft2 Medicine Accelerator Campus in Cherrywood, Dublin, demonstrates our confidence in our team to deliver on that purpose. We are 100% behind them, they are simply extraordinary. As an Irish Multinational company, it also solidifies our confidence in the biopharma ecosystem in Ireland as a global hub, one that is trusted and central to medicine supply chains globally, to drive further innovation in the areas of pharmaceutical R&D, digitalization, and manufacture.

This new expansion will further strengthen our competitiveness through increased integration of the latest developments in sustainability, artificial intelligence, and breakthrough science. It will enable our team to reimagine and transform medicine development and manufacture. I am so excited to see our organization pursue such a patient focused mission.

The support of Enterprise Ireland has been pivotal in accelerating this expansion and we look forward to continuing to work with them on our mission to accelerate medicines to patients.”

The expansion is being supported by Enterprise Ireland, who welcome the creation of high value pharma jobs and the strengthening of Ireland’s position in the global value chain of medicine development and manufacturing.

Welcoming the announcement, Simon Coveney, Minister for Enterprise, Trade and Employment of Ireland, said:

”I want to congratulate Mark and his team at APC & VLE on today’s landmark announcement.  The new Medicine Accelerator Campus demonstrates the capacity of Irish-owned businesses to become world leaders in their field, bringing together technology, innovation and ambition to make a real difference in people’s lives across the globe.

“The government through Enterprise Ireland is committed to scaling and building globally impactful Irish Multinationals that will help drive the Irish economy forward and create high value jobs at home. APC & VLE’s announcement today is testament to that Irish Multinational ambition in action and I am delighted to support them on their patient-focused mission.”

Leo Clancy, CEO of Enterprise Ireland, said:

“Enterprise Ireland is proud to support the ambitious vision behind APC & VLE’s groundbreaking Medicine Accelerator Campus announced today.  The Campus will further enhance Ireland’s global reputation as a leader in the Life Sciences sector and I want to congratulate the entire team at APC & VLE on delivering on this remarkable project.

“One of Enterprise Ireland’s core priorities is to assist Irish owned companies to scale internationally, while creating high-value jobs at home.  Today’s announcement is a concrete example of how this can be achieved and we look forward to continuing to work closely with APC & VLE as they implement their ambitious strategy and delivering innovative health solutions to a global market.”


For more information about APC and VLE, please visit:


Find us on LinkedIn or follow us on Twitter @apcinnovate